General
Preferred name
L-838,417
Synonyms
CTP354 ()
L 838417 ()
CTP-354 ()
L-838417 ()
L838417 ()
P&D ID
PD016793
CAS
286456-42-6
1213669-91-0
Tags
available
drug candidate
Drug indication
Pain
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Subtype-selective GABAA partial agonist (Tocriscreen Plus)
DESCRIPTION Reversible TRPA1 channel blocker (Tocris Bioactive Compound Library)
DESCRIPTION L-838,417 is a subtype-selective GABAA receptor partial agonist. It selectively binds to α2, α3 and α5 subunits with Ki values of 0.67, 0.67 and 2.25 nM respectively, but it shows no efficacy at α1 (α1-sparing). It shows non-sedative antinociceptive, anxiolytic and anti-inflammatory activity in vivo. It was developed by Merck. (BOC Sciences Bioactive Compounds)
Compound Sets
15
AdooQ Bioactive Compound Library
A15939
Axon Medchem Screening Library
1196
BOC Sciences Bioactive Compounds
l-838-417-cas-286456-42-6-item-120590
Cayman Chemical Bioactives
36618
Concise Guide to Pharmacology 2017/18
4241
Concise Guide to Pharmacology 2019/20
4241
Concise Guide to Pharmacology 2021/22
4241
Concise Guide to Pharmacology 2023/24
4241
Drug Repurposing Hub
DrugMAP
DMXY43L
Guide to Pharmacology
4241
Novartis Chemogenetic Library (NIBR MoA Box)
ReFrame library
Tocris Bioactive Compound Library
3250
Tocriscreen Plus
3250
External IDs
23
Properties
(calculated by RDKit )
Molecular Weight
399.16
Hydrogen Bond Acceptors
8
Hydrogen Bond Donors
0
Rotatable Bonds
4
Ring Count
4
Aromatic Ring Count
4
cLogP
3.07
TPSA
83.02
Fraction CSP3
0.32
Chiral centers
0.0
Largest ring
6.0
QED
0.52
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target Type
Ion Channels
Primary Target
GABAA Receptors
MOA
Agonist
GABA(A) BZ Site Receptor Agonists
GABA(A) BZ Site Receptor Antagonists
GABA receptor partial agonist
Member status
member
Target
GABRA1, GABRA2, GABRA3, GABRA5
GABAA-a1 antagonist
Source data